However, there are no commercial presentations of the drug for pediatric patients ( 5). SC was approved for PAH treatment in children by the Food and Drug Administration (FDA) and the European Medicines Agency in 2005 ( 4). This drug inhibits phosphodiesterase 5 (PDE5) by blocking its catalytic site, which prevents the degradation of the cyclic guanosine monophosphate molecule, promoting vascular smooth muscle relaxation and increased blood flow, thus relieving the symptoms of PAH. Several therapies are used to treat PAH however, sildenafil citrate (SC) is one of the most cost-efficient treatments ( 3). Unfortunately, this disease has high mortality and morbidity rates ( 2). CHD is the most frequent birth defect, with a prevalence ranging from 6 to 8 per 1,000 live births. This condition is a progressive disorder characterized by high blood pressure in the pulmonary artery ( 1). Pulmonary arterial hypertension (PAH) is a common complication of congenital heart disease (CHD). These fibers encapsulated approximately 2.5 mg/cm 2 of the drug and achieved immediate controlled released rate, which is encouraging for further studies leading to an alternative treatment of PAH in children. The drug-loaded PVP fibers showed better quality regarding size and homogeneity compared to drug-loaded PVA fibers. The wetting and dissolution time of the scaffolds and drug release rate were studied as well. Surface analysis of the nanofibers was studied by field emission scanning electron microscopy. Thermal stability was studied by thermogravimetric analysis and polymeric transitions by differential scattering calorimetry. The chemical composition of the nanofibers was analyzed by Fourier transform infrared spectroscopy. These fiber scaffolds were prepared through the electrospinning technique. This study aims to synthesize electrospun, submicron fiber scaffolds of poly(vinyl alcohol) (PVA) and poly(vinyl pyrrolidone) (PVP) loaded with SC for fast drug dissolution and its potential use in the treatment of PAH.
Sildenafil citrate (SC) has proved to be an effective and inexpensive drug for the treatment of pulmonary arterial hypertension (PAH).
0 kommentar(er)
